col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


268 Results       Page 1

 [1] 
Elsevier: EBioMedicine
  original article Date Title Authors   All Authors
1 [GO] 2022―Nov―12 Fulminant lung fibrosis in non-resolvable COVID-19 requiring transplantation Soma S.K. Jyothula, Andrew Peters, Yafen Liang, Weizhen Bi, Pooja Shivshankar, Simon Yau, et al. (+13)
2 [GO] 2022―Nov―12 Multivalent S2-based vaccines provide broad protection against SARS-CoV-2 variants of concern and pangolin coronaviruses Peter J. Halfmann, Steven J. Frey, Kathryn Loeffler, Makoto Kuroda, Tadashi Maemura, Tammy Armbrust, et al. (+6)
3 [GO] 2022―Nov―03 Endothelial cells are major players in SARS-CoV-2-related acute respiratory distress syndrome Francesca Caccuri, Arnaldo Caruso
4 [GO] 2022―Nov―01 Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial Nomathemba Chandiwana, Chelsea Kruger, Hilary Johnstone, Mohamed Farouk Chughlay, Chung Ju, Byungsu Kim, et al. (+10)
5 [GO] 2022―Oct―26 Deep-learning-based hepatic fat assessment (DeHFt) on non-contrast chest CT and its association with disease severity in COVID-19 infections: A multi-site retrospective study Gourav Modanwal, Sadeer Al-Kindi, Jonathan Walker, Rohan Dhamdhere, Lei Yuan, Mengyao Ji, et al. (+4)
6 [GO] 2022―Oct―13 Thrombopoietin participates in platelet activation in COVID-19 patients Enrico Lupia, Marialessia Capuano, Barbara Vizio, Martina Schiavello, Ornella Bosco, Maria Gelardi, et al. (+7)
7 [GO] 2022―Oct―10 Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial Meera Madhavan, Adam J. Ritchie, Jeremy Aboagye, Daniel Jenkin, Samuel Provstgaad-Morys, Iona Tarbet, et al. (+16)
8 [GO] 2022―Oct―06 Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications Nicola Potere, Marco Giuseppe Del Buono, Roberto Caricchio, Paul C. Cremer, Alessandra Vecchié, Ettore Porreca, et al. (+4)
9 [GO] 2022―Oct―04 The fatal trajectory of pulmonary COVID-19 is driven by lobular ischemia and fibrotic remodelling Maximilian Ackermann, Jan C. Kamp, Christopher Werlein, Claire L. Walsh, Helge Stark, Verena Prade, et al. (+26)
10 [GO] 2022―Oct―04 A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core Rui Shi, Jiawei Zeng, Ling Xu, Fengze Wang, Xiaomin Duan, Yue Wang, et al. (+5)
11 [GO] 2022―Oct―04 Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2 Emanuel Vogel, Katharina Kocher, Alina Priller, Cho-Chin Cheng, Philipp Steininger, Bo-Hung Liao, et al. (+24)
12 [GO] 2022―Oct―03 Hospital trajectories and early predictors of clinical outcomes differ between SARS-CoV-2 and influenza pneumonia Patrick G. Lyons, Sivasubramanium V. Bhavani, Aaloke Mody, Alice Bewley, Katherine Dittman, Aisling Doyle, et al. (+10)
13 [GO] 2022―Sep―28 Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach Bhargava Kandala, Nele Plock, Akshita Chawla, Anna Largajolli, Seth Robey, Kenny Watson, et al. (+6)
14 [GO] 2022―Sep―28 Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection Gabriella Captur, James C. Moon, Constantin-Cristian Topriceanu, George Joy, Leo Swadling, Jenny Hallqvist, et al. (+20)
15 [GO] 2022―Sep―22 Long COVID symptoms in exposed and infected children, adolescents and their parents one year after SARS-CoV-2 infection: A prospective observational cohort study Anneke Haddad, Aleš Janda, Hanna Renk, Maximilian Stich, Pauline Frieh, Klaus Kaier, et al. (+25)
16 [GO] 2022―Sep―18 SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern Anupriya Aggarwal, Anouschka Akerman, Vanessa Milogiannakis, Mariana Ruiz Silva, Gregory Walker, Alberto Ospina Stella, et al. (+23)
17 [GO] 2022―Sep―07 Protection against SARS-CoV-2 transmission by a parenteral prime-Intranasal boost vaccine strategy Dennis Christensen, Charlotta Polacek, Daniel J. Sheward, Leo Hanke, Ainhoa Moliner-Morro, Gerald McInerney, et al. (+14)
18 [GO] 2022―Aug―27 Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models Ji Ma, Michael Bright Yakass, Sander Jansen, Bert Malengier-Devlies, Dominique Van Looveren, Lorena Sanchez-Felipe, et al. (+9)
19 [GO] 2022―Aug―26 Fatality assessment and variant risk monitoring for COVID-19 using three new hospital occupancy related metrics Ping-Wu Zhang, Steven H. Zhang, Wei-Feng Li, Casey J. Keuthan, Shuaizhang Li, Felipe Takaesu, et al. (+4)
20 [GO] 2022―Aug―24 Diffuse alveolar damage patterns reflect the immunological and molecular heterogeneity in fatal COVID-19 Jonas S. Erjefält, Natália de Souza Xavier Costa, Jimmie Jönsson, Olga Cozzolino, Katia Cristina Dantas, Carl-Magnus Clausson, et al. (+23)
21 [GO] 2022―Aug―18 Replication of SARS-CoV-2 Omicron BA.2 variant in ex vivo cultures of the human upper and lower respiratory tract Kenrie P.Y. Hui, Ka-Chun Ng, John C.W. Ho, Hin-Wo Yeung, Rachel H.H. Ching, Haogao Gu, et al. (+9)
22 [GO] 2022―Aug―18 Antibody response against SARS-CoV-2 variants of concern in children infected with pre-Omicron variants: An observational cohort study Vanesa Seery, Silvina Raiden, Constanza Russo, Mauricio Borda, Largión Herrera, Macarena Uranga, et al. (+27)
23 [GO] 2022―Aug―12 Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials Subhash Thuluva, Vikram Paradkar, Subba Reddy Gunneri, Vijay Yerroju, Rammohan Mogulla, Kishore Turaga, et al. (+7)
24 [GO] 2022―Aug―11 Anti-neuronal antibodies against brainstem antigens are associated with COVID-19 Guglielmo Lucchese, Antje Vogelgesang, Fabian Boesl, Dina Raafat, Silva Holtfreter, Barbara M. Bröker, et al. (+5)
25 [GO] 2022―Aug―09 Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study Al Ozonoff, Joanna Schaenman, Naresh Doni Jayavelu, Carly E. Milliren, Carolyn S. Calfee, Charles B. Cairns, et al. (+333)
26 [GO] 2022―Aug―05 Dysregulation of the kallikrein-kinin system in bronchoalveolar lavage fluid of patients with severe COVID-19 Caroline P. Martens, Pierre Van Mol, Joost Wauters, Els Wauters, Tanja Gangnus, Bernard Noppen, et al. (+23)
27 [GO] 2022―Aug―04 Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine David W. Hawman, Kimberly Meade-White, Chad Clancy, Jacob Archer, Troy Hinkley, Shanna S. Leventhal, et al. (+16)
28 [GO] 2022―Aug―02 Assessing and improving the validity of COVID-19 autopsy studies - A multicentre approach to establish essential standards for immunohistochemical and ultrastructural analyses Susanne Krasemann, Carsten Dittmayer, Saskia von Stillfried, Jenny Meinhardt, Fabian Heinrich, Kristin Hartmann, et al. (+31)
29 [GO] 2022―Jul―30 Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera Amy S. Espeseth, Maoli Yuan, Michael Citron, Lucia Reiserova, Gavin Morrow, Aaron Wilson, et al. (+23)
30 [GO] 2022―Jul―27 Clinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York Ralf Duerr, Dacia Dimartino, Christian Marier, Paul Zappile, Samuel Levine, Fritz Francois, et al. (+8)
31 [GO] 2022―Jul―20 COVID-19 lung disease shares driver AT2 cytopathic features with Idiopathic pulmonary fibrosis Saptarshi Sinha, Vanessa Castillo, Celia R. Espinoza, Courtney Tindle, Ayden G. Fonseca, Jennifer M. Dan, et al. (+4)
32 [GO] 2022―Jul―15 HDL cholesterol levels and susceptibility to COVID-19 Vignesh Chidambaram, Amudha Kumar, Marie Gilbert Majella, Bhavna Seth, Ranjith Kumar Sivakumar, Dinesh Voruganti, et al. (+8)
33 [GO] 2022―Jul―11 Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2 Jean-Sélim Driouich, Maxime Cochin, Franck Touret, Paul-Rémi Petit, Magali Gilles, Grégory Moureau, et al. (+15)
34 [GO] 2022―Jul―11 Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies Alexander Wilhelm, Marek Widera, Katharina Grikscheit, Tuna Toptan, Barbara Schenk, Christiane Pallas, et al. (+9)
35 [GO] 2022―Jul―08 Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade Mar Masiá, Marta Fernández-González, José Alberto García, Sergio Padilla, Javier García-Abellán, Ángela Botella, et al. (+3)
36 [GO] 2022―Jun―30 An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females Natalie Gabrielle Marchevsky, Grace Li, Parvinder Aley, Sue Ann Costa Clemens, Jordan Richard Barrett, Sandra Belij-Rammerstorfer, et al. (+18)
37 [GO] 2022―Jun―29 Recapitulating infection, thermal sensitivity and antiviral treatment of seasonal coronaviruses in human airway organoids Pengfei Li, Yining Wang, Mart M. Lamers, Marla Lavrijsen, Cinta Iriondo, Annemarie C. de Vries, et al. (+4)
38 [GO] 2022―Jun―27 Evidence of previous SARS-CoV-2 infection in seronegative patients with long COVID Benjamin A. Krishna, Eleanor Y. Lim, Lenette Mactavous, Paul A. Lyons, Rainer Doffinger, John R. Bradley, et al. (+6)
39 [GO] 2022―Jun―27 IgG N-glycome changes during the course of severe COVID-19: An observational study Tea Petrović, Amrita Vijay, Frano Vučković, Irena Trbojević-Akmačić, Benjamin J. Ollivere, Damir Marjanović, et al. (+9)
40 [GO] 2022―Jun―27 Multi-ancestry Mendelian randomization of omics traits revealing drug targets of COVID-19 severity Jie Zheng, Yuemiao Zhang, Huiling Zhao, Yi Liu, Denis Baird, Mohd Anisul Karim, et al. (+12)
41 [GO] 2022―Jun―24 Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis Xi Wu, Lu Wang, Lu Shen, Kefu Tang
42 [GO] 2022―May―26 Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients Nicolas Chapuis, Nusaibah Ibrahimi, Thibaut Belmondo, Claire Goulvestre, Anne-Emmanuelle Berger, Alice-Andrée Mariaggi, et al. (+33)
43 [GO] 2022―May―25 Sowing SARS-CoV-2 to reap neurodegeneration: A hamster study S. Rasika, Daniela Fernandois, Vincent Prévot
44 [GO] 2022―May―20 COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents David H. Canaday, Oladayo A. Oyebanji, Elizabeth White, Debbie Keresztesy, Michael Payne, Dennis Wilk, et al. (+11)
45 [GO] 2022―May―06 Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants Matthew R. Chang, Hanzhong Ke, Christian D. Coherd, Yufei Wang, Kiyomi Mashima, Gabriella M. Kastrunes, et al. (+2)
46 [GO] 2022―May―06 SARS-CoV-2 vaccination diversifies the CD4+ spike-reactive T cell repertoire in patients with prior SARS-CoV-2 infection Arbor G. Dykema, Boyang Zhang, Bezawit A. Woldemeskel, Caroline C. Garliss, Rufiaat Rashid, Timothy Westlake, et al. (+9)
47 [GO] 2022―May―05 Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy Maria Pia Sormani, Irene Schiavetti, Matilde Inglese, Luca Carmisciano, Alice Laroni, Caterina Lapucci, et al. (+31)
48 [GO] 2022―Apr―28 Pathogenicity of SARS-CoV-2 Omicron BA.1.1 in hamsters Jasper Fuk-Woo Chan, Hin Chu
49 [GO] 2022―Apr―27 Predicting the efficacy of new coronavirus vaccines - Are neutralising antibodies enough? Elizabeth Miller
50 [GO] 2022―Apr―21 Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies Takuya Tada, Hao Zhou, Belinda M. Dcosta, Marie I. Samanovic, Vidya Chivukula, Ramin S. Herati, et al. (+3)
51 [GO] 2022―Apr―20 The displacement of the SARS-CoV-2 variant Delta with Omicron: An investigation of hospital admissions and upper respiratory viral loads Amary Fall, Raghda E. Eldesouki, Jaiprasath Sachithanandham, C. Paul Morris, Julie M. Norton, David C. Gaston, et al. (+8)
52 [GO] 2022―Apr―19 Multi-omic approach to identify risk markers specific to COVID-19 Won-Young Kim
53 [GO] 2022―Apr―16 Microgliosis and neuronal proteinopathy in brain persist beyond viral clearance in SARS-CoV-2 hamster model Christopher Käufer, Cara S. Schreiber, Anna-Sophia Hartke, Ivo Denden, Stephanie Stanelle-Bertram, Sebastian Beck, et al. (+9)
54 [GO] 2022―Apr―15 Reply to the Letter to the Editor: “Importance of nasal secretions in the evaluation of mucosal immunity elicited by mRNA BNT162b2 COVID-19 vaccine” by Francavilla B et al. Lorenzo Azzi, Daniela Dalla Gasperina, Roberto Sergio Accolla, Greta Forlani
55 [GO] 2022―Apr―14 Importance of nasal secretions in the evaluation of mucosal immunity elicited by mRNA BNT162b2 COVID-19 Vaccine Beatrice Francavilla, Marzia Nuccetelli, Mariapia Guerrieri, Denise Fiorelli, Stefano Di Girolamo
56 [GO] 2022―Apr―12 Tuberculosis vaccines in the era of Covid-19 - what is taking us so long? Hazel M. Dockrell, Helen McShane
57 [GO] 2022―Apr―08 Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines Lu Lu, Lin-Lei Chen, Ricky Rui-Qi Zhang, Owen Tak-Yin Tsang, Jacky Man-Chun Chan, Anthony Raymond Tam, et al. (+15)
58 [GO] 2022―Apr―08 Cardiovascular signatures of COVID-19 predict mortality and identify barrier stabilizing therapies Dakota Gustafson, Michelle Ngai, Ruilin Wu, Huayun Hou, Alice Carvalhal Schoffel, Clara Erice, et al. (+15)
59 [GO] 2022―Apr―08 Lab-in-a-van: Rapid SARS-CoV-2 testing response with a mobile laboratory Susan A Ballard, Maryza Graham, Debra David, Tuyet Hoang, Angela Donald, Michelle Sait, et al. (+6)
60 [GO] 2022―Apr―08 Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern Sreelekshmy Mohandas, Pragya D. Yadav, Gajanan Sapkal, Anita M. Shete, Gururaj Deshpande, Dimpal A. Nyayanit, et al. (+5)
61 [GO] 2022―Apr―04 SARS-CoV-2 entry sites are present in all structural elements of the human glossopharyngeal and vagal nerves: Clinical implications Lynn Vitale-Cross, Ildiko Szalayova, Aiden Scoggins, Miklos Palkovits, Eva Mezey
62 [GO] 2022―Apr―01 Telomere-length dependent T-cell clonal expansion: A model linking ageing to COVID-19 T-cell lymphopenia and mortality James J. Anderson, Ezra Susser, Konstantin G. Arbeev, Anatoliy I. Yashin, Daniel Levy, Simon Verhulst, Abraham Aviv
63 [GO] 2022―Mar―30 Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals Nicolás A. Muena, Tamara García-Salum, Catalina Pardo-Roa, María José Avendaño, Eileen F. Serrano, Jorge Levican, et al. (+15)
64 [GO] 2022―Mar―27 T cell response against SARS-CoV-2 persists after one year in patients surviving severe COVID-19 Fabienne Venet, Morgane Gossez, Frank Bidar, Maxime Bodinier, Rémy Coudereau, Anne-Claire Lukaszewicz, et al. (+19)
65 [GO] 2022―Mar―25 The multifaceted protease-anti-protease imbalance in COVID-19 Khushboo Goel, Karina A. Serban
66 [GO] 2022―Mar―25 Reporting and data sharing level for COVID-19 vaccine trials: A cross-sectional study Yuting Duan, Jingyuan Luo, Lingyun Zhao, Xuan Zhang, Jiangxia Miao, David Moher, Zhaoxiang Bian
67 [GO] 2022―Mar―22 Immunoglobulin G1 Fc glycosylation as an early hallmark of severe COVID-19 Tamas Pongracz, Jan Nouta, Wenjun Wang, Krista E. van Meijgaarden, Federica Linty, Gestur Vidarsson, et al. (+7)
68 [GO] 2022―Mar―16 Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months Guruprasad R Medigeshi, Gaurav Batra, Deepika Rathna Murugesan, Ramachandran Thiruvengadam, Souvick Chattopadhyay, Bhabatosh Das, et al. (+14)
69 [GO] 2022―Mar―14 SARS-CoV-2 mRNA vaccine induced higher antibody affinity and IgG titers against variants of concern in post-partum vs non-post-partum women Youri Lee, Gabrielle Grubbs, Sabrina C. Ramelli, Andrea R. Levine, Allison Bathula, Kapil Saharia, et al. (+19)
70 [GO] 2022―Mar―13 Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2 Nell Saunders, Delphine Planas, William H. Bolland, Christophe Rodriguez, Slim Fourati, Julian Buchrieser, et al. (+19)
71 [GO] 2022―Mar―13 A thermostable Cas12b from Brevibacillus leverages one-pot discrimination of SARS-CoV-2 variants of concern Long T. Nguyen, Nicolas C. Macaluso, Brianna L.M. Pizzano, Melanie N. Cash, Jan Spacek, Jan Karasek, et al. (+5)
72 [GO] 2022―Mar―10 Mesenchymal stem cell treatment for COVID-19 Ruonan Xu, Zhiqian Feng, Fu-Sheng Wang
73 [GO] 2022―Mar―09 Nitric oxide in COVID-19: Too little of a good thing? Michele Ferrari, Alessandro Protti
74 [GO] 2022―Mar―09 Letter to the editor RE: Lake et al., 2022 comment on Fulford et al., 2021 ‘A point-of-care lateral flow assay for neutralizing antibodies against SARS-CoV-2’ David A. Anderson, Dale I. Godfrey
75 [GO] 2022―Mar―05 IgM responses following SARS-CoV-2 vaccination: insights into protective and pre-existing immunity Judith Fraussen
76 [GO] 2022―Mar―03 Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong Qiaoli Peng, Runhong Zhou, Yuewen Wang, Meiqing Zhao, Na Liu, Shuang Li, et al. (+7)
77 [GO] 2022―Feb―26 The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies Alexandra J Spencer, Susan Morris, Marta Ulaszewska, Claire Powers, Reshma Kailath, Cameron Bissett, et al. (+20)
78 [GO] 2022―Feb―24 Letter to the editor RE: Fulford et al., 2021 ‘A point-of-care lateral flow assay for neutralizing antibodies against SARS-CoV-2’ Douglas F. Lake, Alexa J. Roeder, Alim Seit-Nebi, Maria J Gonzalez-Moa, Sergei Svarovsky
79 [GO] 2022―Feb―23 Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients Virginie Montiel, Irina Lobysheva, Ludovic Gérard, Marjorie Vermeersch, David Perez-Morga, Thomas Castelein, et al. (+15)
80 [GO] 2022―Feb―23 Persistent cardiac injury - An important component of long COVID-19 syndrome Vignesh Chidambaram, Amudha Kumar, Giuseppe Calcaterra, Jawahar L. Mehta
81 [GO] 2022―Feb―22 Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications Oisin F. McElvaney, Takanori Asakura, Suzanne L. Meinig, Jose L. Torres-Castillo, Robert S. Hagan, Claudie Gabillard-Lefort, et al. (+18)
82 [GO] 2022―Feb―20 SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals Alessandra Ruggiero, Chiara Piubelli, Lucia Calciano, Simone Accordini, Maria Teresa Valenti, Luca Dalle Carbonare, et al. (+11)
83 [GO] 2022―Feb―19 The impact of hypoxia on B cells in COVID-19 Prasanti Kotagiri, Federica Mescia, Aimee L. Hanson, Lorinda Turner, Laura Bergamaschi, Ana Peñalver, et al. (+16)
84 [GO] 2022―Feb―14 OxVent: Design and evaluation of a rapidly-manufactured Covid-19 ventilator Richard Beale, Jacqueline Beddoe Rosendo, Christos Bergeles, Anair Beverly, Luigi Camporota, Alfonso A. Castrejón-Pita, et al. (+30)
85 [GO] 2022―Feb―07 Clinical predictors of acute cardiac injury and normalization of troponin after hospital discharge from COVID-19 Joyce Q. Lu, Justin Y. Lu, Weihao Wang, Yuhang Liu, Alexandra Buczek, Roman Fleysher, et al. (+5)
86 [GO] 2022―Feb―03 SARS-CoV-2 RNA elements share human sequence identity and upregulate hyaluronan via NamiRNA-enhancer network Wei Li, Shuai Yang, Peng Xu, Dapeng Zhang, Ying Tong, Lu Chen, et al. (+23)
87 [GO] 2022―Jan―24 Intranasal COVID-19 vaccines: From bench to bed Aqu Alu, Li Chen, Hong Lei, Yuquan Wei, Xiaohe Tian, Xiawei Wei
88 [GO] 2022―Jan―23 Do preexisting antibodies against seasonal coronaviruses have a protective role against SARS-CoV-2 infections and impact on COVID-19 severity? Gheyath K. Nasrallah
89 [GO] 2022―Jan―22 Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern Branislav Kovacech, Lubica Fialova, Peter Filipcik, Rostislav Skrabana, Monika Zilkova, Natalia Paulenka-Ivanovova, et al. (+39)
90 [GO] 2022―Jan―21 Association of acute kidney injury with 1-year outcome of kidney function in hospital survivors with COVID-19: A cohort study Xiaoying Gu, Lixue Huang, Dan Cui, Yeming Wang, Yimin Wang, Jiuyang Xu, et al. (+3)
91 [GO] 2022―Jan―16 Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study Odile Launay, Cécile Artaud, Marie Lachâtre, Mohand Ait-Ahmed, Jelle Klein, Liem Binh Luong Nguyen, et al. (+18)
92 [GO] 2022―Jan―15 Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial Frédéric Vanhoutte, Wen Liu, Richard T. Wiedmann, Liesbeth Haspeslagh, Xin Cao, Keith Boundy, et al. (+14)
93 [GO] 2022―Jan―13 Endothelial thrombomodulin downregulation caused by hypoxia contributes to severe infiltration and coagulopathy in COVID-19 patient lungs Taejoon Won, Megan K. Wood, David M. Hughes, Monica V. Talor, Zexu Ma, Jowaly Schneider, et al. (+14)
94 [GO] 2022―Jan―12 Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers Gemma Moncunill, Ruth Aguilar, Marta Ribes, Natalia Ortega, Rocío Rubio, Gemma Salmerón, et al. (+24)
95 [GO] 2022―Jan―06 CRISPRi links COVID-19 GWAS loci to LZTFL1 and RAVER1 Iris M. Fink-Baldauf, William D. Stuart, John J. Brewington, Minzhe Guo, Yutaka Maeda
96 [GO] 2022―Jan―06 Lack of evidence of significant homology of SARS-CoV-2 spike sequences to myocarditis-associated antigens Daniel Marrama, Jarjapu Mahita, Alessandro Sette, Bjoern Peters
97 [GO] 2021―Dec―31 Specific inhibition of the NLRP3 inflammasome suppresses immune overactivation and alleviates COVID-19 like pathology in mice Jianxiong Zeng, Xiaochun Xie, Xiao-Li Feng, Ling Xu, Jian-Bao Han, Dandan Yu, et al. (+6)
98 [GO] 2021―Dec―29 Affinity of anti-spike antibodies in SARS-CoV-2 patient plasma and its effect on COVID-19 antibody assays Patrick J. Macdonald, Qiaoqiao Ruan, Jessica L. Grieshaber, Kerry M. Swift, Russell E. Taylor, John C. Prostko, Sergey Y. Tetin
99 [GO] 2021―Dec―25 Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial Lei Shi, Xin Yuan, Weiqi Yao, Siyu Wang, Chao Zhang, Bo Zhang, et al. (+16)
100 [GO] 2021―Dec―24 Quantitative plasma proteome profiling of COVID-19 patients with mild and moderate symptoms He-wei Jiang, Sheng-ce Tao
101 [GO] 2021―Dec―24 Accuracy and ease-of-use of seven point-of-care SARS-CoV-2 antigen-detecting tests: A multi-centre clinical evaluation Lisa J. Krüger, Amilcar Tanuri, Andreas K. Lindner, Mary Gaeddert, Lisa Köppel, Frank Tobian, et al. (+32)
102 [GO] 2021―Dec―23 Mucosal immune response in BNT162b2 COVID-19 vaccine recipients Lorenzo Azzi, Daniela Dalla Gasperina, Giovanni Veronesi, Mariam Shallak, Giuseppe Ietto, Domenico Iovino, et al. (+12)
103 [GO] 2021―Dec―21 Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models Runhong Zhou, Pui Wang, Yik-Chun Wong, Haoran Xu, Siu-Ying Lau, Li Liu, et al. (+17)
104 [GO] 2021―Dec―17 Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants Rüdiger Groß, Michelle Zanoni, Alina Seidel, Carina Conzelmann, Andrea Gilg, Daniela Krnavek, et al. (+13)
105 [GO] 2021―Dec―16 Developing RT-LAMP assays for rapid diagnosis of SARS-CoV-2 in saliva Xin Huang, Gongyu Tang, Nahed Ismail, Xiaowei Wang
106 [GO] 2021―Dec―15 Linking COVID-19, monocyte activation and sepsis: MDW, a novel biomarker from cytometry Giovanni Riva, Vincenzo Nasillo, Mario Luppi, Enrico Tagliafico, Tommaso Trenti
107 [GO] 2021―Dec―10 Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex Juanjie Tang, Gabrielle Grubbs, Youri Lee, Chang Huang, Supriya Ravichandran, David Forgacs, et al. (+3)
108 [GO] 2021―Dec―03 A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2 Thomas S. Fulford, Huy Van, Nicholas A. Gherardin, Shuning Zheng, Marcin Ciula, Heidi E. Drummer, et al. (+27)
109 [GO] 2021―Nov―30 Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2 Yannick Galipeau, Vinayakumar Siragam, Geneviève Laroche, Erika Marion, Matthew Greig, Michaeline McGuinty, et al. (+8)
110 [GO] 2021―Nov―30 Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial Peter Bergman, Ola Blennow, Lotta Hansson, Stephan Mielke, Piotr Nowak, Puran Chen, et al. (+25)
111 [GO] 2021―Nov―27 Next generation plasma proteome profiling of COVID-19 patients with mild to moderate symptoms Wen Zhong, Ozlem Altay, Muhammad Arif, Fredrik Edfors, Levent Doganay, Adil Mardinoglu, et al. (+2)
112 [GO] 2021―Nov―25 Targeting conserved N-glycosylation blocks SARS-CoV-2 variant infection in vitro Hsiang-Chi Huang, Yun-Ju Lai, Chun-Che Liao, Wang-Feng Yang, Ke-Bin Huang, I-Jung Lee, et al. (+16)
113 [GO] 2021―Nov―19 Current and future nanoparticle vaccines for COVID-19 Mai N. Vu, Hannah G. Kelly, Stephen J. Kent, Adam K. Wheatley
114 [GO] 2021―Nov―17 Alpha variant SARS-CoV-2 infection: How it all starts Pere Domingo, Natividad de Benito
115 [GO] 2021―Nov―11 Genome-wide association study of hospitalized COVID-19 patients in the United Arab Emirates Mira Mousa, Hema Vurivi, Hussein Kannout, Maimunah Uddin, Nawal Alkaabi, Bassam Mahboub, et al. (+2)
116 [GO] 2021―Nov―10 Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two? Philippine Eloy, Roger Le Grand, Denis Malvy, Jérémie Guedj
117 [GO] 2021―Nov―10 T cells as the hoped-for savior for SARS-CoV-2 vaccination during CD20-depleting antibody therapy? Gabriel Bsteh, Johann Sellner
118 [GO] 2021―Nov―08 Safety and Cross-Variant Immunogenicity of a Three-dose COVID-19 mRNA Vaccine Regimen in Kidney Transplant Recipients Filippo Massa, Marion Cremoni, Alexandre Gérard, Hanen Grabsi, Lory Rogier, Mathilde Blois, et al. (+14)
119 [GO] 2021―Nov―07 Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model Kyle L. O'Donnell, Amanda N. Pinski, Chad S. Clancy, Tylisha Gourdine, Kyle Shifflett, Paige Fletcher, et al. (+2)
120 [GO] 2021―Nov―03 Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines Youchun Wang
121 [GO] 2021―Nov―03 Complex immune deregulation in severe COVID-19: More than a mechanism of pathogenesis Evangelos J. Giamarellos-Bourboulis
122 [GO] 2021―Oct―30 Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response Jesús Ontañón, Joaquín Blas, Carlos de Cabo, Celia Santos, Elena Ruiz-Escribano, Antonio García, et al. (+9)
123 [GO] 2021―Oct―22 Severe COVID-19 is characterized by the co-occurrence of moderate cytokine inflammation and severe monocyte dysregulation Benjamin Bonnet, Justine Cosme, Claire Dupuis, Elisabeth Coupez, Mireille Adda, Laure Calvet, et al. (+7)
124 [GO] 2021―Oct―22 Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients Juan Manuel Carreño, Hala Alshammary, Gagandeep Singh, Ariel Raskin, Fatima Amanat, Angela Amoako, et al. (+9)
125 [GO] 2021―Oct―22 Emerging SARS-CoV-2 variants expand species tropism to murines Huiping Shuai, Jasper Fuk-Woo Chan, Terrence Tsz-Tai Yuen, Chaemin Yoon, Jing-Chu Hu, Lei Wen, et al. (+25)
126 [GO] 2021―Oct―20 Off balance: Interferons in COVID-19 lung infections Milena Apetito Akamatsu, Júlia Tavares de Castro, Carolina Yumi Takano, Paulo Lee Ho
127 [GO] 2021―Oct―19 Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy Sachin P. Gadani, Maria Reyes-Mantilla, Larissa Jank, Samantha Harris, Morgan Douglas, Matthew D. Smith, et al. (+4)
128 [GO] 2021―Oct―15 SARS-CoV-2 vaccination in multiple sclerosis: A clearer picture for the time point during CD20 depleting therapy Eva C. Schulte, Johann Sellner
129 [GO] 2021―Oct―14 Host genetic factors determining COVID-19 susceptibility and severity Thirumalaisamy P. Velavan, Srinivas Reddy Pallerla, Jule Rüter, Yolanda Augustin, Peter G. Kremsner, Sanjeev Krishna, Christian G. Meyer
130 [GO] 2021―Oct―12 A poor and delayed anti-SARS-CoV2 IgG response is associated to severe COVID-19 in children Inés Sananez, Silvina C. Raiden, Silvia C. Algieri, Macarena Uranga, Nicolás A. Grisolía, Daniela Filippo, et al. (+43)
131 [GO] 2021―Oct―08 Immunogenic T cell epitopes of SARS-CoV-2 are recognized by circulating memory and naïve CD8 T cells of unexposed individuals Isaac Quiros-Fernandez, Mansour Poorebrahim, Elham Fakhr, Angel Cid-Arregui
132 [GO] 2021―Oct―04 Corrigendum to “Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge” [EBioMedicine 2 (2015) 1438-1446] Jiaming Lan, Yanfeng Yao, Yao Deng, Hong Chen, Guangwen Lu, Wen Wang, et al. (+6)
133 [GO] 2021―Sep―24 Immunological response after mild COVID-19: How long will it last? Adriana Balduzzi
134 [GO] 2021―Sep―24 The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model Rana Abdelnabi, Caroline S. Foo, Suzanne J.F. Kaptein, Xin Zhang, Thuc Nguyen Dan Do, Lana Langendries, et al. (+16)
135 [GO] 2021―Sep―24 Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination Brent Appelman, Karlijn van der Straten, A.H. Ayesha Lavell, Michiel Schinkel, Marleen A. Slim, Meliawati Poniman, et al. (+11)
136 [GO] 2021―Sep―22 Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies Maria Pia Sormani, Matilde Inglese, Irene Schiavetti, Luca Carmisciano, Alice Laroni, Caterina Lapucci, et al. (+29)
137 [GO] 2021―Sep―17 The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data Aharona Glatman-Freedman, Michal Bromberg, Rita Dichtiar, Yael Hershkovitz, Lital Keinan-Boker
138 [GO] 2021―Sep―15 Vaccination after prior COVID-19 infection: Implications for dose sparing and booster shots Stephen J Kent, Jennifer A Juno
139 [GO] 2021―Sep―12 Is preexisting immunity to seasonal coronaviruses limited to cross-reactivity with SARS-CoV-2? A seroprevalence cross-sectional study in north-eastern France Hadeel T. Zedan, Gheyath K. Nasrallah
140 [GO] 2021―Aug―27 Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection Floriane Gallais, Pierre Gantner, Timothée Bruel, Aurélie Velay, Delphine Planas, Marie-Josée Wendling, et al. (+20)
141 [GO] 2021―Aug―26 Vaccine against SARS-CoV-2 in previously infected health care workers Saverio Giuseppe Parisi
142 [GO] 2021―Aug―26 Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis Paul Martin, Candice Clarke
143 [GO] 2021―Aug―24 COVID-19 and malaria, a tale of two diseases EBioMedicine
144 [GO] 2021―Aug―19 Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19 Alexander P. Underwood, Christina Sølund, Carlota Fernandez-Antunez, Signe Lysemose Villadsen, Anni Assing Winckelmann, Signe Bollerup, et al. (+9)
145 [GO] 2021―Aug―19 The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum Lu Lu, Allen Wing-Ho Chu, Ricky Ruiqi Zhang, Wan-Mui Chan, Jonathan Daniel Ip, Hoi-Wah Tsoi, et al. (+19)
146 [GO] 2021―Aug―12 B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19 Andreas Zollner, Christina Watschinger, Annika Rössler, Maria R. Farcet, Agnes Penner, Vincent Böhm, et al. (+9)
147 [GO] 2021―Aug―12 Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2 Sebastian Havervall, Ulrika Marking, Nina Greilert-Norin, Henry Ng, Max Gordon, Ann-Christin Salomonsson, et al. (+10)
148 [GO] 2021―Aug―12 Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis Monika Strengert, Matthias Becker, Gema Morillas Ramos, Alex Dulovic, Jens Gruber, Jennifer Juengling, et al. (+13)
149 [GO] 2021―Aug―12 Identification of COVID-19 prognostic markers and therapeutic targets through meta-analysis and validation of Omics data from nasopharyngeal samples Abhijith Biji, Oyahida Khatun, Shachee Swaraj, Rohan Narayan, Raju S. Rajmani, Rahila Sardar, et al. (+8)
150 [GO] 2021―Aug―12 Persistence of immunity to SARS-CoV-2 over time in the ski resort Ischgl Wegene Borena, Zoltán Bánki, Katie Bates, Hannes Winner, Lydia Riepler, Annika Rössler, et al. (+14)
151 [GO] 2021―Aug―12 High throughput diagnostics and dynamic risk assessment of SARS-CoV-2 variants of concern Alfredo Maria Gravagnuolo, Layla Faqih, Cara Cronshaw, Jacquelyn Wynn, Paul Klapper, Mark Wigglesworth
152 [GO] 2021―Jul―29 Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up Nelly Kanberg, Joel Simrén, Arvid Edén, Lars-Magnus Andersson, Staffan Nilsson, Nicholas J. Ashton, et al. (+5)
153 [GO] 2021―Jul―29 Short telomeres and severe COVID-19: The connection conundrum Abraham Aviv
154 [GO] 2021―Jul―29 A dried blood spot protocol for high throughput analysis of SARS-CoV-2 serology based on the Roche Elecsys anti-N assay Jessica Beyerl, Raquel Rubio-Acero, Noemi Castelletti, Ivana Paunovic, Inge Kroidl, Zohaib N. Khan, et al. (+5)
155 [GO] 2021―Jul―23 Shorter leukocyte telomere length is associated with adverse COVID-19 outcomes: A cohort study in UK Biobank Qingning Wang, Veryan Codd, Zahra Raisi-Estabragh, Crispin Musicha, Vasiliki Bountziouka, Stephen Kaptoge, et al. (+10)
156 [GO] 2021―Jul―23 SARS-CoV-2 activates lung epithelial cell proinflammatory signaling and leads to immune dysregulation in COVID-19 patients Huarong Chen, Weixin Liu, Yifei Wang, Dabin Liu, Liuyang Zhao, Jun Yu
157 [GO] 2021―Jul―23 Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France Tom Woudenberg, Stéphane Pelleau, François Anna, Mikael Attia, Françoise Donnadieu, Alain Gravet, et al. (+32)
158 [GO] 2021―Jul―17 COVID-19 rapid antigen testing strategies require careful evaluation Jacqueline Dinnes
159 [GO] 2021―Jul―10 Unleashing immuno-mass spectrometry superpowers to detect SARS-CoV-2 Jean Armengaud
160 [GO] 2021―Jul―03 Fibrotic lung disease: A molecular glimpse into severe Covid-19? Paolo Spagnolo, Justin M Oldham
161 [GO] 2021―Jul―03 A mass spectrometry-based targeted assay for detection of SARS-CoV-2 antigen from clinical specimens Santosh Renuse, Patrick M. Vanderboom, Anthony D. Maus, Jennifer V. Kemp, Kari M. Gurtner, Anil K. Madugundu, et al. (+11)
162 [GO] 2021―Jun―26 NK cells on the ViP stage of COVID-19 Elena Masselli, Marco Vitale
163 [GO] 2021―Jun―26 Corrigendum to “itraconazole for COVID-19: Preclinical studies and a proof-of-concept randomized clinical trial Laurens” Laurens Liesenborghs, Isabel Spriet, Dirk Jochmans, Ann Belmans, Iwein Gyselinck, Laure-Anne Teuwen, et al. (+33)
164 [GO] 2021―Jun―26 Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR Isabell Wagenhäuser, Kerstin Knies, Vera Rauschenberger, Michael Eisenmann, Miriam McDonogh, Nils Petri, et al. (+14)
165 [GO] 2021―Jun―20 50-gene risk profiles in peripheral blood predict COVID-19 outcomes: A retrospective, multicenter cohort study Brenda M. Juan Guardela, Jiehuan Sun, Tong Zhang, Bing Xu, Joseph Balnis, Yong Huang, et al. (+7)
166 [GO] 2021―Jun―13 Letter to the Editor re: Baldassarri et al., 2021 “Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males” Soha Ghanian, Carlos G. Wambier
167 [GO] 2021―Jun―13 In response to the letter to the editor by Soha Ghanian et al. re our publication “Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males” Andrea M. Isidori, Marco Marcelli, Maria Grazia Castagna, Margherita Baldassarri, Francesca Fava, Alessandra Renieri
168 [GO] 2021―Jun―11 AI-guided discovery of the invariant host response to viral pandemics Debashis Sahoo, Gajanan D. Katkar, Soni Khandelwal, Mahdi Behroozikhah, Amanraj Claire, Vanessa Castillo, et al. (+16)
169 [GO] 2021―Jun―04 Procoagulant activity of extracellular vesicles in plasma of patients with SARS-CoV-2 infection L. Theresa
170 [GO] 2021―Jun―04 Accuracy of four lateral flow immunoassays for anti SARS-CoV-2 antibodies: a head-to-head comparative study Hayley E Jones, Ranya Mulchandani, Sian Taylor-Phillips, A E Ades, Justin Shute, Keith R Perry, et al. (+9)
171 [GO] 2021―Jun―04 SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity Stine SF Nielsen, Line K Vibholm, Ida Monrad, Rikke Olesen, Giacomo S Frattari, Marie H Pahus, et al. (+9)
172 [GO] 2021―Jun―04 SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic Matthieu Schoenhals, Niry Rabenindrina, Jean Marius Rakotondramanga, Philippe Dussart, Rindra Randremanana, Jean-Michel Heraud, et al. (+7)
173 [GO] 2021―May―26 SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors Matthew Frieman, Anthony D. Harris, Ramin Sedaghat Herati, Florian Krammer, Alberto Mantovani, Maria Rescigno, et al. (+2)
174 [GO] 2021―May―25 Biomarkers for severe COVID-19 Xin Li, Kelvin K.W. To
175 [GO] 2021―May―25 A lethal mouse model using a mouse-adapted SARS-CoV-2 strain with enhanced binding to mouse ACE2 as an important platform for COVID-19 research Hin Chu, Jasper Fuk-Woo Chan
176 [GO] 2021―May―25 Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters Rana Abdelnabi, Robbert Boudewijns, Caroline S. Foo, Laura Seldeslachts, Lorena Sanchez-Felipe, Xin Zhang, et al. (+7)
177 [GO] 2021―May―14 Clinical features and prognostic factors in Covid-19: A prospective cohort study Sanne de Bruin, Lieuwe D. Bos, Marian A. van Roon, Anita M. Tuip-de Boer, Alex R. Schuurman, Marleen J.A. Koel-Simmelinck, et al. (+10)
178 [GO] 2021―May―14 Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice Kun Huang, Yufei Zhang, Xianfeng Hui, Ya Zhao, Wenxiao Gong, Ting Wang, et al. (+11)
179 [GO] 2021―May―14 Defective NET clearance contributes to sustained FXII activation in COVID-19-associated pulmonary thrombo-inflammation Hanna Englert, Chandini Rangaswamy, Carsten Deppermann, Jan-Peter Sperhake, Christoph Krisp, Danny Schreier, et al. (+14)
180 [GO] 2021―May―13 An epigenetic signature to fight COVID-19 Georges Herbein
181 [GO] 2021―May―13 HERV-W envelope expression in blood leukocytes as a marker of disease severity of COVID-19 Marta Garcia-Montojo, Avindra Nath
182 [GO] 2021―May―09 Blood neutrophils from children with COVID-19 exhibit both inflammatory and anti-inflammatory markers Vanesa Seery, Silvina C. Raiden, Silvia C. Algieri, Nicolás A. Grisolía, Daniela Filippo, Norberto De Carli, et al. (+29)
183 [GO] 2021―May―07 Circulating extracellular vesicles are endowed with enhanced procoagulant activity in SARS-CoV-2 infection Carolina Balbi, Jacopo Burrello, Sara Bolis, Edoardo Lazzarini, Vanessa Biemmi, Enea Pianezzi, et al. (+8)
184 [GO] 2021―Apr―26 Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series Thao T. Truong, Alex Ryutov, Utsav Pandey, Rebecca Yee, Lior Goldberg, Deepa Bhojwani, et al. (+21)
185 [GO] 2021―Apr―25 The duplicitous nature of ACE2 in COVID-19 disease EBioMedicine (invited commentary) Samuel N. Heyman, Safa Kinaneh, Zaid Abassi
186 [GO] 2021―Apr―25 Research on COVID-19 therapy: Putting the cart alongside the horse Alexandre Duvignaud, Xavier Anglaret
187 [GO] 2021―Apr―25 A comprehensive antigen production and characterisation study for easy-to-implement, specific and quantitative SARS-CoV-2 serotests Miriam Klausberger, Mark Duerkop, Helmuth Haslacher, Gordana Wozniak-Knopp, Monika Cserjan-Puschmann, Thomas Perkmann, et al. (+52)
188 [GO] 2021―Apr―16 Evidence of the pathogenic HERV-W envelope expression in T lymphocytes in association with the respiratory outcome of COVID-19 patients Emanuela Balestrieri, Antonella Minutolo, Vita Petrone, Marialaura Fanelli, Marco Iannetta, Vincenzo Malagnino, et al. (+13)
189 [GO] 2021―Apr―16 Epigenome-wide association study of COVID-19 severity with respiratory failure Manuel Castro de Moura, Veronica Davalos, Laura Planas-Serra, Damiana Alvarez-Errico, Carles Arribas, Montserrat Ruiz, et al. (+26)
190 [GO] 2021―Apr―14 Corrigendum to ‘Simpler and faster Covid-19 testing: Strategies to streamline SARS-CoV-2 molecular assays’ Nuttada Panpradist, Qin Wang, Parker S. Ruth, Jack H. Kotnik, Amy K. Oreskovic, Abraham Miller, et al. (+7)
191 [GO] 2021―Apr―14 'Geno-to-pheno' SARS-CoV-2 genome-COVID-19 association studies Julian W Tang
192 [GO] 2021―Apr―14 High dimensional cytokine panels reveal common SARS-CoV-2-related inflammation patterns across different latitudes Paolo Palma
193 [GO] 2021―Apr―08 Association of SARS-CoV-2 clades with clinical, inflammatory and virologic outcomes: An observational study Barnaby E Young, Wycliffe E Wei, Siew-Wai Fong, Tze-Minn Mak, Danielle E Anderson, Yi-Hao Chan, et al. (+20)
194 [GO] 2021―Apr―02 Plasma biomarker profiling of PIMS-TS, COVID-19 and SARS-CoV2 seropositive children - a cross-sectional observational study from southern India. Aishwarya Venkataraman, Nathella Pavan Kumar, Luke Elizabeth Hanna, Sulochana Putlibai, M Karthick, Anuradha Rajamanikam, et al. (+3)
195 [GO] 2021―Apr―02 The contrasting role of nasopharyngeal angiotensin converting enzyme 2 (ACE2) transcription in SARS-CoV-2 infection: A cross-sectional study of people tested for COVID-19 in British Columbia, Canada Aidan M. Nikiforuk, Kevin S. Kuchinski, David D.W. Twa, Christine D. Lukac, Hind Sbihi, C.Andrew Basham, et al. (+6)
196 [GO] 2021―Apr―02 Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge Martin S. Winkler, Tomasz Skirecki, Frank M. Brunkhorst, Sara Cajander, Jean-Marc Cavaillon, Ricard Ferrer, et al. (+17)
197 [GO] 2021―Mar―21 Androgenicity-not serum testosterone-correlates best with COVID-19 outcome in European males Luca Giovanelli, Richard Quinton
198 [GO] 2021―Mar―21 Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial Laurens Liesenborghs, Isabel Spriet, Dirk Jochmans, Ann Belmans, Iwein Gyselinck, Laure-Anne Teuwen, et al. (+33)
199 [GO] 2021―Mar―11 Shared genetic etiology between idiopathic pulmonary fibrosis and COVID-19 severity João Fadista, Luke M. Kraven, Juha Karjalainen, Shea J. Andrews, Frank Geller, J Kenneth Baillie, et al. (+3)
200 [GO] 2021―Mar―08 Temporal dynamics of the host molecular responses underlying severe COVID-19 progression and disease resolution Eugenia Z Ong, Shirin Kalimuddin, Wen Chong Chia, Sarah H Ooi, Clara WT Koh, Hwee Cheng Tan, et al. (+4)
201 [GO] 2021―Mar―07 Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity Markus Hoffmann, Heike Hofmann-Winkler, Joan C. Smith, Nadine Krüger, Prerna Arora, Lambert K. Sørensen, et al. (+17)
202 [GO] 2021―Mar―02 Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS-CoV-2 infection Charlotte Manisty, Thomas Alexander Treibel, Melanie Jensen, Amanda Semper, George Joy, Rishi K Gupta, et al. (+22)
203 [GO] 2021―Feb―26 Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males Margherita Baldassarri, Nicola Picchiotti, Francesca Fava, Chiara Fallerini, Elisa Benetti, Sergio Daga, et al. (+34)
204 [GO] 2021―Feb―25 COVID-19-associated surge of atopic dermatitis
205 [GO] 2021―Feb―24 Non-communicable diseases pandemic and precision medicine: Is Africa ready? Tinashe Chikowore, Abram Bunya Kamiza, Ovokeraye H. Oduaran, Tafadzwa Machipisa, Segun Fatumo
206 [GO] 2021―Feb―12 Simpler and faster Covid-19 testing: Strategies to streamline SARS-CoV-2 molecular assays Nuttada Panpradist, Qin Wang, Parker S. Ruth, Jack H. Kotnik, Amy K. Oreskovic, Abraham Miller, et al. (+7)
207 [GO] 2021―Feb―10 Persistent viral RNA shedding in COVID-19: Caution, not fear Mario Plebani
208 [GO] 2021―Feb―06 Evaluating the effects of cardiometabolic exposures on circulating proteins which may contribute to severe SARS-CoV-2 Tom G Richardson, Si Fang, Ruth E Mitchell, Michael V Holmes, George Davey Smith
209 [GO] 2021―Jan―30 SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses Line K Vibholm, Stine SF Nielsen, Marie H Pahus, Giacomo S Frattari, Rikke Olesen, Rebecca Andersen, et al. (+11)
210 [GO] 2021―Jan―10 Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19 Michael G. Ison, Marc H. Scheetz
211 [GO] 2021―Jan―10 A breath of fresh air - the potential for COVID-19 breath diagnostics Cristina E. Davis, Michael Schivo, Nicholas J. Kenyon
212 [GO] 2021―Jan―10 SARS-CoV-2 leads to a small vessel endotheliitis in the heart Umberto Maccio, Annelies S. Zinkernagel, Srikanth Mairpady Shambat, Xiankun Zeng, Gieri Cathomas, Frank Ruschitzka, et al. (+3)
213 [GO] 2021―Jan―10 Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice Katharina Wørzner, Daniel J. Sheward, Signe Tandrup Schmidt, Leo Hanke, Julie Zimmermann, Gerald McInerney, et al. (+4)
214 [GO] 2020―Dec―17 Reducing transmission of SARS-CoV-2 with intranasal prophylaxis Federico Boiardi, Justin Stebbing
215 [GO] 2020―Dec―09 COVID-19 reinfection: are we ready for winter?
216 [GO] 2020―Dec―04 Metabolomics of exhaled breath in critically ill COVID-19 patients: A pilot study Stanislas Grassin-Delyle, Camille Roquencourt, Pierre Moine, Gabriel Saffroy, Stanislas Carn, Nicholas Heming, et al. (+7)
217 [GO] 2020―Dec―03 Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model Pamela C. Proud, Daphne Tsitoura, Robert J. Watson, Brendon Y. Chua, Marilyn J. Aram, Kevin R. Bewley, et al. (+20)
218 [GO] 2020―Nov―21 Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate Weina Sun, Sarah R. Leist, Stephen McCroskery, Yonghong Liu, Stefan Slamanig, Justine Oliva, et al. (+7)
219 [GO] 2020―Nov―11 A clade of SARS-CoV-2 viruses associated with lower viral loads in patient upper airways Ramon Lorenzo-Redondo, Hannah H. Nam, Scott C. Roberts, Lacy M. Simons, Lawrence J. Jennings, Chao Qi, et al. (+5)
220 [GO] 2020―Nov―10 Corrigendum to ‘A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19 Oliver J McElvaney, Brian D Hobbs, Dandi Qiao, Oisín F McElvaney, Matthew Moll, Natalie L McEvoy, et al. (+6)
221 [GO] 2020―Nov―05 Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity Andrea Padoan, Francesco Bonfante, Matteo Pagliari, Alessio Bortolami, Davide Negrini, Silvia Zuin, et al. (+4)
222 [GO] 2020―Nov―05 SARS-CoV-2 antibody-based SURVEILLANCE: New light in the SHADOW Mario Plebani
223 [GO] 2020―Nov―04 Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology Rossana Bussani, Edoardo Schneider, Lorena Zentilin, Chiara Collesi, Hashim Ali, Luca Braga, et al. (+7)
224 [GO] 2020―Nov―03 Predicting outcomes in COVID-19: From internal validation to improving care Ryeyan Taseen, André M. Cantin
225 [GO] 2020―Oct―23 COVID-19 and lombardy: TESTing the impact of the first wave of the pandemic Luca Perico, Susanna Tomasoni, Tobia Peracchi, Annalisa Perna, Anna Pezzotta, Giuseppe Remuzzi, Ariela Benigni
226 [GO] 2020―Oct―21 Blockade of an innate immune amplifier to fight immune hyperactivation in COVID-19? Alexandra K. Kiemer
227 [GO] 2020―Oct―09 A CRISPR-Cas12a-based specific enhancer for more sensitive detection of SARS-CoV-2 infection Weiren Huang, Lei Yu, Donghua Wen, Dong Wei, Yangyang Sun, Huailong Zhao, et al. (+38)
228 [GO] 2020―Oct―08 A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19 Oliver J McElvaney, Brian D Hobbs, Dandi Qiao, Oisín F McElvaney, Matthew Moll, Natalie L McEvoy, et al. (+6)
229 [GO] 2020―Oct―07 The role for the metagenome in the pathogenesis of COVID-19 Robert P Friedland, Bodduluri Haribabu
230 [GO] 2020―Oct―07 Tocilizumab is recommended for the treatment of severe COVID-19 Yonggang Zhou, Haiming Wei
231 [GO] 2020―Sep―25 Characterizing COVID-19 maternal-fetal transmission and placental infection using comprehensive molecular pathology David A. Schwartz, Kristen M. Thomas
232 [GO] 2020―Sep―24 Differential expression of ACE2 in the respiratory tracts and its relationship to COVID-19 pathogenesis Chunxiu Yang, Yueying Li, Shu-Yuan Xiao
233 [GO] 2020―Sep―22 Positive, again! What to make of “re-positive” SARS-CoV-2 molecular test results Viviana Simon, Harm van Bakel, Emilia Mia Sordillo
234 [GO] 2020―Sep―16 Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study Mar Masiá, Marta Fernández-González, Sergio Padilla, Piedad Ortega, José A. García, Vanesa Agulló, et al. (+4)
235 [GO] 2020―Aug―30 Monocyte activation in systemic Covid-19 infection: Assay and rationale Fernando O. Martinez, Theo W. Combes, Federica Orsenigo, Siamon Gordon
236 [GO] 2020―Aug―25 Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients Baranca Buijsers, Cansu Yanginlar, Marissa L. Maciej-Hulme, Quirijn de Mast, Johan van der Vlag
237 [GO] 2020―Aug―24 Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR Jing Lu, Jinju Peng, Qianling Xiong, Zhe Liu, Huifang Lin, Xiaohua Tan, et al. (+12)
238 [GO] 2020―Aug―20 COVID-19 and vascular disease
239 [GO] 2020―Aug―17 Risk of stroke in hospitalized SARS-CoV-2 infected patients: A multinational study Shima Shahjouei, Soheil Naderi, Jiang Li, Ayesha Khan, Durgesh Chaudhary, Ghasem Farahmand, et al. (+38)
240 [GO] 2020―Aug―17 SARS-CoV2 vertical transmission with adverse effects on the newborn revealed through integrated immunohistochemical, electron microscopy and molecular analyses of Placenta Fabio Facchetti, Mattia Bugatti, Emma Drera, Claudio Tripodo, Enrico Sartori, Valeria Cancila, et al. (+6)
241 [GO] 2020―Aug―15 Immunothrombosis in severe COVID-19 Daigo Nakazawa, Akihiro Ishizu
242 [GO] 2020―Aug―15 Antibody responses in mild COVID-19 hospital staff Mario Plebani
243 [GO] 2020―Aug―15 Early prediction of the risk of severe coronavirus disease 2019: A key step in therapeutic decision making Andréanne Côté, Julien Ternacle, Philippe Pibarot
244 [GO] 2020―Aug―15 Immunodominant epitopes based serological assay for detecting SARS-CoV-2 exposure: Promises and challenges Ahmed Abdul Q귮r
245 [GO] 2020―Aug―06 SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy Mina K. Chung, Sadashiva Karnik, Joshua Saef, Cornelia Bergmann, John Barnard, Michael M. Lederman, et al. (+14)
246 [GO] 2020―Jul―31 Vascular occlusion by neutrophil extracellular traps in COVID-19 Moritz Leppkes, Jasmin Knopf, Elisabeth Naschberger, Aylin Lindemann, Jeeshan Singh, Irmgard Herrmann, et al. (+17)
247 [GO] 2020―Jul―31 Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France Samira Fafi-Kremer, Timothée Bruel, Yoann Madec, Rebecca Grant, Laura Tondeur, Ludivine Grzelak, et al. (+20)
248 [GO] 2020―Jul―29 The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19) Pere Domingo, Isabel Mur, Virginia Pomar, Héctor Corominas, Jordi Casademont, Natividad de Benito
249 [GO] 2020―Jul―24 SARS-CoV-2 detection in different respiratory sites: A systematic review and meta-analysis Abbas Mohammadi, Elmira Esmaeilzadeh, Yijia Li, Ronald J. Bosch, Jonathan Z. Li
250 [GO] 2020―Jul―22 Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: A systematic review and meta-analysis Anne Weiss, Mads Jellingsø, Morten Otto Alexander Sommer
251 [GO] 2020―Jul―22 Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity Siti Naqiah Amrun, Cheryl Yi-Pin Lee, Bernett Lee, Siew-Wai Fong, Barnaby Edward Young, Rhonda Sin-Ling Chee, et al. (+18)
252 [GO] 2020―Jul―21 Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections Ren Yang, Jiaming Lan, Baoying Huang, Ruhan A, Mingqing Lu, Wen Wang, et al. (+5)
253 [GO] 2020―Jul―07 Reappearance of effector T cells is associated with recovery from COVID-19 Ivan Odak, Joana Barros-Martins, Berislav Bošnjak, Klaus Stahl, Sascha David, Olaf Wiesner, et al. (+13)
254 [GO] 2020―Jul―07 Development and validation of the HNC-LL score for predicting the severity of coronavirus disease 2019 Lu-shan Xiao, Wen-Feng Zhang, Meng-chun Gong, Yan-pei Zhang, Li-ya Chen, Hong-bo Zhu, et al. (+4)
255 [GO] 2020―Jul―03 Illuminating COVID-19 lung disease through autopsy studies David K. Meyerholz, Paul B. McCray
256 [GO] 2020―Jun―21 COVID-19: A time for renewed recognition of science
257 [GO] 2020―Jun―20 Targeting innate immunity by blocking CD14: Novel approach to control inflammation and organ dysfunction in COVID-19 illness Thomas R. Martin, Mark M. Wurfel, Ivan Zanoni, Richard Ulevitch
258 [GO] 2020―Jun―20 Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients Chaofu Wang, Jing Xie, Lei Zhao, Xiaochun Fei, Heng Zhang, Yun Tan, et al. (+20)
259 [GO] 2020―Jun―20 Mendelian randomization in COVID-19: Applications for cardiovascular comorbidities and beyond Yaqun Teng, Jiuyang Xu, Yang Zhang, Zhenyu Liu, Shuyang Zhang
260 [GO] 2020―Jun―11 Merits and culprits of immunotherapies for neurological diseases in times of COVID-19 Marc Pawlitzki, Uwe K. Zettl, Tobias Ruck, Leoni Rolfes, Hans-Peter Hartung, Sven G. Meuth
261 [GO] 2020―May―28 Infectivity of human coronavirus in the brain Qi Cheng, Yue Yang, Jianqun Gao
262 [GO] 2020―May―23 COVID-19 as a STING disorder with delayed over-secretion of interferon-beta Jean-Marie Berthelot, Frédéric Lioté
263 [GO] 2020―May―22 Race for a COVID-19 vaccine
264 [GO] 2020―May―07 A glimpse into the eye of the COVID-19 cytokine storm Krutika Kuppalli, Angela L. Rasmussen
265 [GO] 2020―Apr―21 Sedating ventilated COVID-19 patients with inhalational anesthetic drugs Beverley A. Orser, Dian-Shi Wang, Wei-Yang Lu
266 [GO] 2020―Apr―18 Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients Jing Liu, Sumeng Li, Jia Liu, Boyun Liang, Xiaobei Wang, Hua Wang, et al. (+44)
267 [GO] 2020―Apr―16 Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development Ruklanthi de Alwis, Shiwei Chen, Esther S. Gan, Eng Eong Ooi
268 [GO] 2020―Apr―02 Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development Eun Kim, Geza Erdos, Shaohua Huang, Thomas W. Kenniston, Stephen C. Balmert, Cara Donahue Carey, et al. (+7)
 [1] 

268 Results       Page 1



[de][en]

Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.123 sec